Diabetes Therapy
Repaglinide lowers glycohemoglobin level effectively and safely
Published in Obesity and Diabetes Week, May 24th, 2004
"A total of 385 drug-therapy naive patients, with inadequately controlled type 2 diabetes, were randomized into a multinational, parallel-group study to compare two strategies for dose titration of the oral hypoglycemic agent repaglinide. Patients were allocated to either a fasting blood glucose (FBG) monitoring group with titration target 4.4-6.1 mmol/L or to a postprandial blood glucose (PPBG) monitoring group with titration target 4.4-8.0 mmol/L," an international team of scientists reports.
"An initial titration period of up to 8 weeks was followed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity and Diabetes
Adiponectin does not rise upon weight loss in insulin-resistant women - Obesity and Diabetes
Four-week high carbohydrate/low fat diet reduces insulin resistance - Obesity and Diabetes
Neuropeptide Y, galanin deletions yield obesity and endocrine problems - Polycystic Ovary Disease
Normal p21Ras/MAP kinase pathway found in polycystic ovary disease - Addiction Medicine
Sensitivity to reward can result in overeating and obesity - Atherosclerosis Therapy
Lipoprotein lipase activator offers promise for atherosclerosis therapy - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
